{"filings":[{"id":1895356,"accession_number":"0001193125-26-318853","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2026-07-28T11:13:43+00:00","items":["2.02","9.01"],"status":"ready","headline":"Repligen Q2 revenue $204M (+13% organic), adj EPS $0.54; raises FY guidance; acquires BioLife","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $204M, +12% reported, +13% organic; adjusted EPS $0.54 vs $0.37 prior year.","GAAP operating income flat at $14M; GAAP EPS $0.09 (down from $0.26).","Full year 2026 guidance raised: organic growth 10.5%-13.5%, adjusted EPS $2.03-$2.09.","Announced definitive agreement to acquire BioLife Solutions, strengthening cell therapy position.","Cash and marketable securities $810M at June 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1785476,"accession_number":"0001193125-26-311402","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2026-07-22T12:56:58+00:00","items":["1.01","2.02","7.01","8.01","9.01"],"status":"ready","headline":"Repligen to acquire BioLife Solutions for ~$1.5B; reports preliminary Q2 revenue growth of ~12%","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Repligen to acquire BioLife for ~$1.5B; per share consideration $31.00 ($11.25 cash + 0.1442 RGEN shares).","Deal expected to close Q4 2026; boards unanimously approved; subject to BLFS stockholder approval and HSR clearance.","Expected to be accretive: at least $0.05 adjusted EPS in year one, at least $0.25 in year two.","Repligen preliminary Q2 revenue growth ~12% (13% organic); BioLife preliminary Q2 revenue growth ~21% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":452756,"accession_number":"0001193125-26-225380","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2026-05-15T12:09:23+00:00","items":["5.07"],"status":"ready","headline":"Repligen 2026 annual meeting: all proposals pass; director Muir gets 25.7% against","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected; Glenn P. Muir received highest opposition (13.3M against, 25.7% of votes cast).","Karen A. Dawes and Carrie Eglinton Manner each received over 9M against votes (17.7% and 19.1%, respectively).","Ratification of Ernst & Young as independent auditor passed with 53.1M for vs 900k against.","Advisory vote on executive compensation approved: 50.3M for, 1.5M against, 51k abstain.","Quorum of 54.0M shares represented out of 56.4M outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98570,"accession_number":"0001193125-26-205011","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Repligen Q1 revenue $194M (+11% organic); raises adjusted EPS guidance to $1.97-$2.05","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $194M, +15% reported/+11% organic; GAAP EPS $0.15, adjusted EPS $0.48 (+23% YoY).","Adjusted operating margin expanded 160bps to 15.4%; gross margin improved to 55.5% (adj.).","FY2026 guidance: revenue $803M-$833M (9-13% organic growth); adj. EPS raised to $1.97-$2.05.","Divested non-core Polymem filtration business (Mar 30); signed China OEM partnership in April.","Transformation Office launched to drive margin expansion, site rationalization, IT/AI investments."],"consensus_eps_estimate":null,"consensus_eps_actual":0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":194255000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114135,"accession_number":"0001193125-26-065246","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Repligen Q4 revenue $198M (+18%); FY26 guidance $810-840M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $198M, up 18% reported and 14% organic YoY; full year 2025 revenue $738M (+16% reported and organic non-COVID).","Q4 GAAP EPS $0.23 vs ($0.60); adjusted EPS $0.49 vs $0.44. Full year adjusted EPS $1.71 vs $1.58.","FY26 revenue guidance $810M–$840M (10-14% reported, 9-13% organic); adjusted operating margin expansion of 150 bps at midpoint.","Full year 2025 organic growth of 14% exceeded initial guidance range; adjusted operating margins improved 90 bps YoY.","CEO cited strong finish led by Analytics and Proteins; new office in Singapore and product launches in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":738256000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114134,"accession_number":"0001193125-26-003467","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Repligen elects Martin D. Madaus as Chair, succeeding Tony Hunt effective Mar 13, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tony Hunt retires as Executive Chair and Board member effective March 13, 2026; will serve as advisor through March 2027.","Dr. Martin D. Madaus, a director since February 2023, elected as Chair of the Board effective March 13, 2026.","Madaus brings 36 years of bioprocessing industry experience; formerly Chairman, President and CEO of Millipore.","The succession was previously disclosed in Repligen's June 14, 2024 8-K filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130515,"accession_number":"0001193125-25-252385","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Repligen Q3 revenue $189M (+22% YoY); raises FY2025 guidance to $729-737M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $189M, +22% reported, +18% organic; double-digit growth across all franchises.","GAAP EPS $0.26 versus ($0.01) loss; adjusted EPS $0.46 versus $0.43.","GAAP gross margin 53.2% (up from 50.0%); adjusted operating margin 14.2%.","Orders grew >20% YoY and sequentially; consumables and capital equipment >20%.","FY2025 revenue guidance raised to $729-737M; adjusted EPS $1.65-$1.68."],"consensus_eps_estimate":null,"consensus_eps_actual":0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":540343000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147069,"accession_number":"0001193125-25-193481","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Repligen appoints Violetta Hughes as Chief Accounting Officer, effective Sept 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Replaces Jason K. Garland as principal accounting officer; Garland remains CFO focusing on strategy.","Annual base salary $395,000, signing bonus $150,000, target annual performance bonus up to 50% of base.","Equity award of $750,000 total ($500k RSUs, $250k options) vesting over 5 years.","Ms. Hughes previously CAO at Azenta (AZTA) and Akebia Therapeutics (AKBA); 25+ years experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147068,"accession_number":"0000950170-25-099389","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Repligen Q2 revenue $182M (+17% organic non-COVID); orders >20% YoY; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $182M, up 15% reported and 17% organic non-COVID YoY.","GAAP EPS $0.26 vs $0.10; adjusted EPS $0.37 vs $0.40.","Orders grew >20% YoY and sequentially, 8th consecutive quarter of orders exceeding non-COVID revenue.","Raises FY2025 revenue guidance to $715-$735M, organic non-COVID growth 12.5%-15.5%.","All franchises grew YoY; consumables >20%, biopharma +20%, all geographies mid-teens."],"consensus_eps_estimate":null,"consensus_eps_actual":0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":351538000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165605,"accession_number":"0000950170-25-072664","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Repligen shareholders approve officer liability limitation amendment, elect directors at May 15 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved a Certificate of Amendment to limit officer liability under Delaware law (45.3M for, 5.9M against).","All 10 director nominees elected, including Olivier Loeillot and Martin Madaus (latter received ~45.6M for, ~5.6M against).","Ernst & Young LLP ratified as independent auditor for fiscal year ending Dec 31, 2025 (52.7M for, 0.6M against).","Advisory vote on named executive officer compensation passed (49.4M for, 1.7M against).","Voter turnout was 94.94% of 56.2M shares entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165604,"accession_number":"0000950170-25-059569","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Repligen Q1 revenue $169M (+10% YoY); adjusted EPS $0.39 vs $0.30; orders up high-teens","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $169M, up 10% reported, 14% organic non-COVID YoY; GAAP EPS $0.10, adjusted EPS $0.39.","Adjusted operating income $23M, up 72% YoY; adjusted gross margin 53.7% vs 49.2%.","Orders grew high-teens YoY with all four franchises up double-digits; biopharma and consumables record ex-COVID.","FY2025 guidance reiterated: organic growth 9.5%-13.5%; adjusted EPS $1.63-$1.72.","Closed acquisition of 908 Devices' bioprocessing portfolio; minimal tariff impact expected."],"consensus_eps_estimate":null,"consensus_eps_actual":0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":169172000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183227,"accession_number":"0000950170-25-023742","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Repligen Q4 revenue $168M; FY2024 $634M; guides FY2025 8-12% growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $168M, flat YoY; FY2024 revenue $634M vs $632M.","GAAP net loss $34M ($0.60 loss per share); adjusted EPS $0.44 vs $0.48.","Orders outpaced sales by 6% in Q4; sequential revenue up 8%.","FY2025 guidance: revenue $685-710M (8-12% reported growth, 10-14% ex-COVID).","Closed acquisition of Tantti Laboratory; launched AVIPure dsRNA resin for mRNA."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":634439000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199808,"accession_number":"0001193125-24-255167","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Repligen Q3 revenue $155M (+10% YoY); adjusted EPS $0.43 vs $0.23","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss ($0.7M) vs income $17M; adjusted net income $24M vs $13M.","Adjusted gross margin 50.7%; adjusted operating margin 14.9% vs 3.7%.","Full-year 2024 revenue guidance narrowed to $630-$639M (midpoint unchanged).","CDMO revenue and orders each grew ~20% YoY; new modalities record quarterly revenue.","Announced definitive agreement to acquire chromatography firm Tantti Laboratory Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":466892000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215827,"accession_number":"0001193125-24-221406","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2024-09-18T23:59:59+00:00","items":["2.02","7.01","4.02","9.01"],"status":"ready","headline":"Repligen restates financials for 2023-2024 due to $17.3M revenue timing error; material weakness identified","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Restatement covers Q1'23 through Q2'24; $17.3M payment from cancelled COVID orders was mis-timed.","Impact: Q1'23 revenue overstated by $17.3M; FY'23 revenue overstated by $6.6M; H1'24 understated by $6.6M.","Material weakness identified in internal control over revenue recognition; no fraud or misconduct.","2024 revenue guidance reaffirmed and updated to $627M-$642M due to timing shift; total revenue unchanged.","No impact on cash, operations, or strategic outlook."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215826,"accession_number":"0001193125-24-188277","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Repligen Q2 revenue $154M, adj. EPS $0.33, orders $157M; CEO transition, Tantti acquisition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 revenue $154M vs $159M prior year; GAAP EPS $0.06, adjusted EPS $0.33 vs $0.53.","Book-to-bill 1.02 for quarter; orders $157M; new modalities sales up 5% YoY.","CEO Tony Hunt becomes Executive Chair; Olivier Loeillot appointed President & CEO effective Sept 1.","Post-quarter-end, entered agreement to acquire chromatography innovator Tantti Laboratory Inc. (value undisclosed).","FY 2024 revenue guidance narrowed to $620-635M; adjusted EPS guidance unchanged at $1.42-1.49."],"consensus_eps_estimate":null,"consensus_eps_actual":0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":305419000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215825,"accession_number":"0001193125-24-179061","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Repligen reports unauthorized access to files on its information systems","summary_kind":"llm","event_type":"cyber","confidence":"high","bullets":["Unauthorized third party accessed certain files on July 9, 2024; response procedures activated immediately.","External cybersecurity experts engaged; law enforcement notified.","No impact on business operations, customer service, or financial condition expected.","Systems remain operational and undisrupted; no malware encryption detected.","Investigation ongoing to determine full scope and any required regulatory notifications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235254,"accession_number":"0001193125-24-161728","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Repligen appoints Olivier Loeillot as CEO effective Sept 1, 2024; Hunt becomes Executive Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Loeillot receives $750K base salary, 85% target bonus, and a $5M equity award (50% RSUs, 25% options, 25% PSUs).","Hunt to serve as Executive Chair through March 2026, then advisor to March 2027; base salary $440K, 52.5% bonus.","Severance: Loeillot gets 1.5x salary for termination without cause; 2.0x salary plus bonus for change-in-control.","Karen Dawes appointed Lead Independent Director, effective Sept 1, 2024; Board composition otherwise unchanged.","Loeillot elected to the Board effective on the transition date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235253,"accession_number":"0001193125-24-160292","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Repligen CEO Tony Hunt to become Executive Chair; Olivier Loeillot appointed President and CEO effective Sept 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tony Hunt transitions from CEO to Executive Chair effective Sept 1, 2024; Olivier Loeillot named President and CEO.","Loeillot, currently President & Chief Commercial Officer (since Oct 2023), will join the Board.","Current Board Chair Karen Dawes becomes Lead Independent Director effective Sept 1, 2024.","Under Hunt's 9-year tenure, Repligen revenue grew from ~$63M (2014) to $639M (2023), ~30% CAGR.","Loeillot has ~30 years industry experience, previously Bioprocess President at Cytiva."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235252,"accession_number":"0001193125-24-141217","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Repligen shareholders elect all nine directors, ratify EY, approve say-on-pay at 2024 meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected with votes for ranging from ~45.95M to ~49.48M.","Ernst & Young ratified as auditor for FY2024: 50.2M for, 2.6M against.","Advisory say-on-pay approved: 46.6M for, 2.8M against, 66K abstain.","Voter turnout was 94.68% of 55.8M shares outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235251,"accession_number":"0001193125-24-126349","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Repligen Q1 revenue falls 17% to $151M; GAAP EPS $0.04, adjusted EPS $0.28","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $151.3M, down from $182.7M YoY; GAAP net income $2.1M ($0.04 diluted EPS) vs $28.8M ($0.51).","Adjusted net income $15.8M ($0.28 diluted EPS) vs $36.3M ($0.64); adjusted gross margin 48.6% vs 55.2%.","New modalities revenue up 16% YoY; Filtration (non-COVID) up 12% YoY; book-to-bill 0.99 (Q1), 1.03 (nine-month).","FY2024 guidance reaffirmed: revenue $620M-$650M, adjusted EPS $1.42-$1.49, adjusted op margin 13%-14%.","Cash and investments $780.6M as of March 31, 2024; Metenova added over $5M revenue in Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":151346000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253091,"accession_number":"0001193125-24-070768","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Repligen appoints Maggie A. Pax to Board of Directors, expanding to nine members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pax elected to board effective March 18, 2024; board expands from eight to nine members.","Pax brings 25+ years in life sciences, including Thermo Fisher VP Strategy and Innovation (2016-2020).","Pax received initial option valued at $215,000 vesting over three years, plus pro-rata equity awards.","Pax is independent under Nasdaq standards; no committee assignments yet.","Pax also serves on boards of Alimera Sciences, Jellagen, and BioPorto U.S. subsidiary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253090,"accession_number":"0001193125-24-040727","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Repligen Q4 revenue down 16.6% to $155.7M; net loss $0.46/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $155.7M vs $186.8M in Q4 2022; full year $638.8M vs $801.5M.","GAAP net loss $25.5M ($0.46 per diluted share) vs profit of $48.7M ($0.85) in Q4 2022.","Adjusted EPS $0.33 vs $0.68; book-to-bill ratio 1.03 for second straight quarter.","FY2024 guidance: revenue $620M-$650M, adjusted EPS $1.42-$1.49.","Closed Metenova acquisition; launched TangenX SC; issued $600M convertible notes."],"consensus_eps_estimate":null,"consensus_eps_actual":0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":638764000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270548,"accession_number":"0001193125-23-296692","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2023-12-15T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Repligen issues $600M of 1.00% convertible notes due 2028, exchanges ~$310M of 2024 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $600M aggregate principal of 1.00% Convertible Senior Notes due 2028, with ~$309.9M exchanged for existing 0.375% 2024 notes and ~$290.1M cash.","Initial conversion price ~$203.06 per share, representing ~30% premium over Dec 6 closing price of $156.20.","Notes mature Dec 15, 2028; redeemable at company option after Dec 18, 2026 under stock price conditions.","Up to 3,841,200 shares of common stock may be issued upon conversion (including make-whole shares).","Following transactions, ~$69.7M of the original 2024 notes remain outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270547,"accession_number":"0001193125-23-290319","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2023-12-07T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Repligen issues $600M of 1% convertible notes due 2028, exchanges $217.7M of 2024 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issues $600M aggregate 1.00% Convertible Senior Notes due 2028; $309.9M exchanged for $217.7M of 0.375% notes due 2024, $290.1M for cash.","Conversion price ~$203.06 per share, representing ~30% premium over Dec 6 close of $156.20.","Net cash proceeds from subscription ~$276.2M; $14.4M to repurchase common stock from certain note purchasers.","Expects to close Dec 14; about $69.7M of 2024 notes remain outstanding.","Notes are senior unsecured, convertible into cash/stock at company's election, redeemable after Dec 2026 under conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270546,"accession_number":"0001193125-23-266741","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2023-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Repligen Q3 revenue $141.2M (-30% YoY); narrows FY2023 outlook, sees order recovery","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $141.2M, base business $140.1M; GAAP EPS $0.32, adjusted EPS $0.23.","Book-to-bill ratio of 1.07; orders strengthened, especially from Pharma customers.","Narrows FY2023 revenue guidance to $635-645M (prev. $635-665M); lowers adj. operating margin to 15-16%.","Restructuring charges of $24M in operating income; acquired Metenova AB on Oct 2 for $164M cash + $9M equity."],"consensus_eps_estimate":null,"consensus_eps_actual":1.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":483021000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270545,"accession_number":"0001193125-23-248189","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2023-10-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Repligen appoints Olivier Loeillot as President and CCO; Hunt remains CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Loeillot appointed President and Chief Commercial Officer effective Oct 2, 2023; reports to CEO Tony Hunt.","Base salary $600k, target bonus 75% of base, signing bonus $1.35M, equity $4M vesting over 5 years.","Hunt relinquishes President role effective Oct 2 but remains CEO; Loeillot has 20+ yr bioprocess experience from Cytiva/GE and Lonza."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287486,"accession_number":"0001193125-23-241886","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2023-09-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Repligen to acquire Metenova for cash and equity; adds magnetic mixing technology","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Metenova projected FY2023 revenue $24-25M; ~50 employees; magnetic mixers for bioprocess.","Expected close Q4 2023; funded with ~$604M cash on hand (cash + equity consideration).","Metenova expected to contribute $5M revenue in Q4 2023, $25-27M in 2024, 20-25% growth in 2025.","Deal projected accretive to adjusted gross/operating margins in 2024 and adjusted EPS in 2025.","Adds single-use MixOne platform; complements Repligen's fluid management and FlexBiosys bag business."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287485,"accession_number":"0001193125-23-233111","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2023-09-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Repligen appoints Jason K. Garland as CFO, replacing retiring Jon Snodgres","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Garland (ex-Integer CFO) named CFO effective Sept 25, 2023; Snodgres remains advisor through Oct 6.","Annual base salary $550,000, target bonus 75% of base, signing bonus $100,000.","Initial equity grants of $1.75M (50% options, 50% RSUs) vesting over 5 years.","2024 annual equity award valued at $875,000 split among time-based RSUs, options, and performance RSUs.","Garland brings 25+ years experience including CFO of a $4B GE division and $1.4B Integer revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287484,"accession_number":"0001193125-23-201167","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Repligen Q2 revenue down 23%; slashes FY2023 revenue guidance to $635-$665M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $159.2M (-23.3% YoY); base business revenue down 8.7%.","GAAP diluted EPS $0.35 vs $0.88 in Q2 2022; adjusted EPS $0.53 vs $0.91.","Full-year revenue guidance cut to $635-$665M from $720-$760M, a 27% reduction at midpoint.","Base business now expected to decline 5-10% in FY2023 vs prior guidance of +4-8%.","CEO cites inventory overhang and longer purchase approvals; Filtration segment most impacted."],"consensus_eps_estimate":null,"consensus_eps_actual":0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":341829000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.88,"calibrated_materiality_score":0.88,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307663,"accession_number":"0001193125-23-150037","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Repligen shareholders approve charter amendment allowing board to amend bylaws at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Eight directors elected including Tony J. Hunt; all nominees received majority support.","Ernst & Young LLP ratified as independent auditor for fiscal year ending December 31, 2023.","Say-on-pay approved with ~96% of votes cast in favor; annual frequency selected for future votes.","Charter amendment approved giving board authority to adopt, amend, or repeal bylaws.","Ratification of amended bylaws implementing shareholder proxy access passed with 99.9% support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307662,"accession_number":"0001193125-23-131300","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2023-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Repligen Q1 revenue $182.7M, down 12% YoY; cuts full-year guidance on macro headwinds","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $0.51 (down 37% YoY); adjusted EPS $0.64 (down 30% YoY); gross margin 55.2% (down 520 bps).","Total revenue guidance cut to $720-760M (prev $760-800M); base business growth lowered to 4-8% (prev 11-15%).","Completed acquisition of single-use bag maker FlexBiosys in April; adds to Fluid Management portfolio.","Sees softness in AsiaPac (especially China) and slower order recovery; COVID-related revenue expected $30-40M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":182660000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307661,"accession_number":"0001193125-23-104254","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2023-04-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Repligen completes acquisition of FlexBiosys Inc. on April 17, 2023","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Completed acquisition of all outstanding equity of FlexBiosys Inc. on April 17, 2023.","Equity Purchase Agreement signed April 12, 2023, with sellers TSAP Holdings, Gayle Tarry, and Stanley Tarry.","No deal value or financial terms disclosed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307660,"accession_number":"0001193125-23-098461","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2023-04-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Repligen announces acquisition of FlexBiosys for undisclosed cash, equity, and earnout","summary_kind":"llm","event_type":"m_and_a","confidence":"low","bullets":["Repligen executed Equity Purchase Agreement to acquire all outstanding equity of FlexBiosys.","Consideration comprises cash, equity, and performance-based earnout payments through year-end 2024.","Transaction expected to close in Q2 2023, subject to satisfaction of conditions.","No financial terms or valuation were disclosed in the SEC filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326645,"accession_number":"0001193125-23-044164","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2023-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Repligen Q4 revenue flat YoY at $186.8M; guides 2023 revenue down 5% to $760-800M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP EPS $0.85 (up from $0.50 YoY); adjusted EPS $0.68 (down from $0.81).","Full year 2022 revenue $801.5M (+20% YoY); base organic growth 39%.","2023 guidance: revenue $760-800M (down from 2022 due to $100-110M COVID decline); base organic growth 12-16%.","Gross margin declines: Q4 GAAP 51.4% (down 460 bps), full year 56.9%; 2023 guided 52.5-53.5%.","Launched 10 new products in 2022; cell/gene therapy revenue grew >50%; signed 2 partnerships."],"consensus_eps_estimate":null,"consensus_eps_actual":3.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":801536000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326644,"accession_number":"0001193125-23-029218","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2023-02-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Repligen appoints Martin D. Madaus to board; board expands to 8","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Martin Madaus, Ph.D., joined Repligen's board effective Feb 6, 2023, also named to Nominating and Corporate Governance Committee.","Board size increased from seven to eight directors upon Madaus' election.","Madaus received initial option grant valued at $170,000, vesting equally over three years.","Pro-rata equity award of options and RSUs each valued at $21,250, vesting at next annual shareholder meeting.","Madaus brings over 25 years of life sciences tools industry experience, including CEO roles at Millipore and Ortho Clinical Diagnostics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344357,"accession_number":"0001193125-22-274508","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2022-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Repligen Q3 revenue $200.7M (+13% YoY); raises FY revenue guidance to $795-$805M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $200.7M, +13% reported, +19% constant currency, +16% organic; base business up 29% YoY.","GAAP EPS $0.71; adjusted EPS $0.77 (vs $0.78 Q3 2021); GAAP gross margin 56.9%.","FY 2022 revenue guidance raised to $795-$805M (from $790-$810M); base business growth raised to 33%-34%.","Adjusted EPS guidance narrowed to $3.15-$3.20 from $3.13-$3.20; operating income guidance lowered to $231-$235M.","Signed 15-year real-time process monitoring deal with DRS Daylight Solutions; extended Purolite affinity ligand agreement to 2032."],"consensus_eps_estimate":null,"consensus_eps_actual":2.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":614774000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":360868,"accession_number":"0001193125-22-209439","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2022-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Repligen Q2 revenue $207.6M (+27% YoY); raises FY 2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $207.6M, up 27% as reported, 32% constant currency; organic growth 29%.","GAAP diluted EPS $0.88 vs $0.64; adjusted EPS $0.91 vs $0.79, both YoY increases.","FY 2022 revenue guidance raised to $790-$810M from $770-$800M; adjusted EPS raised to $3.13-$3.20.","Base business grew 41% in Q2, led by Filtration and Chromatography franchises.","Cash $596.5M at June 30, 2022; gross margin 58.5% GAAP, 58.7% adjusted."],"consensus_eps_estimate":null,"consensus_eps_actual":1.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":414033000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":379986,"accession_number":"0001193125-22-165344","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2022-06-01T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"Repligen appoints Dr. Konstantin Konstantinov to board; all directors re-elected at annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Konstantinov elected to board effective May 26, 2022; brings 30 years of bioprocessing expertise from Genzyme and Bayer.","Annual meeting results: all six director nominees elected with >94% support; Ernst & Young ratified as auditor; say-on-pay approved.","Severance and change in control plan amended to adjust treatment of performance-based equity awards upon change in control.","CEO Tony Hunt's employment agreement amended to align equity treatment with the amended severance plan.","Director compensation policy amended for new non-employee director equity grants; new director granted initial option worth $170,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":379985,"accession_number":"0001193125-22-121628","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2022-04-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Repligen Q1 revenue $206.4M (+45% YoY); lowers FY2022 revenue guidance on COVID decline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q1 revenue of $206.4M (+45% YoY); GAAP EPS $0.81, adjusted EPS $0.92.","Base business grew 37% YoY; gene therapy revenue up >100%.","FY2022 revenue guidance lowered to $770-800M (from $800-830M) due to lower COVID demand.","Base business revenue growth guidance raised to 24%-31% (from 20%-22%).","Cash $584.6M at quarter end; gross margin improved 190 bps to 60.1%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":206400000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":398138,"accession_number":"0001193125-22-068716","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2022-03-08T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Repligen elects combination settlement for convertible notes due 2024","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Irrevocably elected Combination Settlement with $1,000 Specified Dollar Amount per $1,000 principal for 0.375% Convertible Senior Notes due 2024.","Settlement method change applies to any conversion of Notes on or after March 4, 2022.","Notes convertible at holder option upon satisfaction of conditions until April 15, 2024, then at any time.","Second Supplemental Indenture entered with Wilmington Trust, National Association, as trustee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":398137,"accession_number":"0001193125-22-044916","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2022-02-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Repligen Q4 revenue $186.5M (+72% YoY); FY 2022 guidance $800-830M (19-24% growth)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $186.5M (+72% YoY, organic +69%); GAAP EPS $0.50, adjusted EPS $0.81.","FY 2021 revenue $670.5M (+83% YoY); GAAP EPS $2.24, adjusted EPS $3.06.","FY 2022 revenue guidance $800-830M (19-24% growth); adjusted EPS guidance $3.21-$3.30.","Base business contributed 66% of FY revenue; Filtration segment grew ~130% for the year.","Completed acquisition of BioFlex Solutions; cash $603.8M at year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":2.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":670534000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":398136,"accession_number":"0001193125-22-001024","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2022-01-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Repligen promotes James Bylund to Chief Operating Officer effective Jan 1, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Bylund promoted from SVP, Operations & IT to COO and principal operating officer, effective Jan 1, 2022.","Bylund joined Repligen in March 2020; prior 10 years at Thermo Fisher as VP & GM of Single Use Technologies.","He also held leadership roles at Fiserv (9 years) and Eli Lilly (7 years); holds B.S. from Utah State and MBA from Indiana."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":417153,"accession_number":"0001193125-21-358541","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2021-12-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Repligen acquires Bio-Flex Solutions and Newton T&M for cash; terms undisclosed","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Acquired all outstanding equity interests in Bio-Flex Solutions and Newton T&M effective Dec 16, 2021.","Purchase price is cash consideration; no dollar amount disclosed in the filing.","Bio-Flex Solutions specializes in single-use flexible containers and tubing assemblies for biopharma.","Transaction complements Repligen's fluid management portfolio; investor presentation provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":417152,"accession_number":"0001193125-21-310408","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2021-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Repligen Q3 revenue $178.2M (+89% YoY); raises FY 2021 revenue guidance to $655-665M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue hit a record $178.2M in Q3 2021, up 89% YoY as reported and 77% organically.","GAAP EPS of $0.58, Adjusted EPS of $0.78; GAAP operating margin rose to 25.4%.","FY 2021 revenue guidance raised to $655-665M (prior $625-645M); adjusted EPS guidance raised to $2.86-$2.91.","Completed acquisition of affinity ligands innovator Avitide Inc. during the quarter.","COVID programs contributed 27% of Q3 revenue; base business grew 49% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":1.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":484013000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":434711,"accession_number":"0001193125-21-274670","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2021-09-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Repligen to acquire Avitide for ~$150M in cash and stock, adding affinity chromatography capabilities","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration ~$150M, consisting of $75M cash and $75M in Repligen common stock, plus three-year earnout.","Avitide expected to contribute ~$10M revenue in 2022 and be accretive to adjusted EPS in 2023.","Transaction strengthens Repligen's affinity ligand discovery platform for gene therapy and other modalities.","Deal expected to close in Q3 2021; funded with cash on hand ($734M at June 30, 2021)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":434710,"accession_number":"0001193125-21-265002","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2021-09-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Repligen extends Cytiva supply agreement for ligand manufacture through 2025","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Long-term supply agreement with Cytiva Sweden AB extended through 2025.","Covers contract manufacture of Cytiva ligands at Repligen's Waltham, MA and Lund, Sweden facilities.","No financial terms or volume commitments disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":434709,"accession_number":"0001193125-21-225040","cik":730272,"company_name":"REPLIGEN CORP","ticker":"RGEN","form_type":"8-K","filed_at":"2021-07-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Repligen Q2 revenue $163M (+86% YoY); adj. EPS $0.79; raises FY21 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $163.0M, up 86% YoY as reported and 69% organic; base business grew 35% YoY.","GAAP diluted EPS $0.64 vs $0.30; adjusted diluted EPS $0.79 vs $0.42.","GAAP gross margin 62.0% (up 410 bps); adjusted operating margin 34.7% (up 550 bps).","FY2021 revenue guidance raised to $625-645M (prev $565-590M); organic growth guidance 57-62% (prev 42-49%).","Completed acquisition of Polymem S.A. on July 1, 2021; cash position $734.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":1.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":305797000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6383663814.367479,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}